PRODUCT CODE: ET1611-79

Bcl10 Recombinant Rabbit Monoclonal Antibody [SN74-04] (ET1611-79)

  • Recombinant

Applications

  • WB

  • ICC

  • IF

  • IHC-P

  • IP

REACTIVITY

  • Human

Western blot analysis of Bcl10 on different cell lysates using anti-Bcl10 antibody at 1/500 dilution.<br />
Positive control: <br />
Lane 1: HUVEC<br />
Lane 2:SW480
  • Western blot analysis of Bcl10 on different cell lysates using anti-Bcl10 antibody at 1/500 dilution.<br />
Positive control: <br />
Lane 1: HUVEC<br />
Lane 2:SW480
  • ICC staining Bcl10 in MCF-7 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
  • ICC staining Bcl10 in SW480 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
  • Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-Bcl10 antibody. Counter stained with hematoxylin.
Western blot analysis of Bcl10 on different cell lysates using anti-Bcl10 antibody at 1/500 dilution.
Positive control:
Lane 1: HUVEC
Lane 2:SW480

Applications

  • WB

  • ICC

  • IF

  • IHC-P

  • IP

REACTIVITY

  • Human

SPECIFICATIONS

Product Type

Recombinant Rabbit monoclonal primary

Product Name

Bcl10 Recombinant Rabbit Monoclonal Antibody [SN74-04] (ET1611-79)

Immunogen

Recombinant protein

Host

Rabbit

Positive Control

SW480, MCF-7, human tonsil tissue.

Conjugation

Unconjugated

Clonality

Monoclonal

Clone Number

SN74-04

PROPERTIES

Form

Liquid

Storage Condition

Store at +4C after thawing. Aliquot store at -20C or -80C. Avoid repeated freeze / thaw cycles.

Storage Buffer

1*TBS (pH7.4), 0.05% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.

Concentration

1 ug/ul

PURIFICATION

Protein A purified.

MOLECULAR WEIGHT

31 kDa

Isotype

IgG

APPLICATION DILUTION

  • WB

  • 1:1,000

  • ICC/IF

  • 1:50-1:200

  • IHC-P

  • 1:50-1:200

TARGET

UNIPROT #

PROTEIN NAME

Bcl10

SYNONYMS

AI132454 antibody; B cell CLL/lymphoma 10 antibody; B cell lymphoma/leukemia10 antibody; B-cell CLL/lymphoma 10 antibody; B-cell leukemia/lymphoma 10 antibody; B-cell lymphoma/leukemia 10 antibody; Bcl 10 antibody; Bcl-10 antibody; Bcl10 antibody; BCL10_HUMAN antibody; c E10 antibody; c-E10 antibody; C81403 antibody; CARD containing apoptotic signaling protein antibody; CARD containing molecule enhancing NF kappa B antibody; CARD containing molecule enhancing NF kB antibody; CARD containing molecule enhancing NF-kB antibody; CARD containing molecule enhancing NFkB antibody; CARD containing proapoptotic protein antibody; CARD like apoptotic protein antibody; CARD-containing apoptotic signaling protein antibody; CARD-containing molecule enhancing NF-kappa-B antibody; CARD-containing proapoptotic protein antibody; CARD-like apoptotic protein antibody; CARMEN antibody; Caspase recruiting domain containing protein antibody; caspase-recruiting domain-containing protein antibody; cCARMEN antibody; cE 10 antibody; cE10 antibody; CED 3/ICH 1 prodomain homologous E10 like regulator antibody; CED-3/ICH-1 prodomain homologous E10-like regulator antibody; CED3/ICH1 prodomain homologous E10 like regulator antibody; Cellular E10 antibody; Cellular homolog of vCARMEN antibody; Cellular-E10 antibody; CIPER antibody; CLAP antibody; hCLAP antibody; Mammalian CARD containing adapter molecule E10 antibody; Mammalian CARD-containing adapter molecule E10 antibody; mE 10 antibody; mE10 antibody; R-RCD1 antibody

TISSUE SPECIFICITY

Ubiquitous.

POST-TRANSLATIONAL MODIFICATION

Phosphorylated. Phosphorylation results in dissociation from TRAF2 and binding to BIRC2/c-IAP2. Phosphorylated by IKBKB/IKKB.

SUBCELLULAR LOCATION

Cytoplasm, Membrane raft.

FUNCTION

Bcl10, also designated CIPER, c-CARMEN and mE10, was first identified as a gene truncated or mutated in MALT B cell lymphomas and other tumor types. Bcl10 is homologous to the equine herpesvirus-2 E10 gene and, like E10, it contains an N-terminal caspase recruitment domain (CARD). Expression of Bcl10 has been shown to induce NFκB activation in a NIK-dependent pathway, and research indicates that the CARD domain is essential for this activation; although in a separate study, Bcl10 by itself did not induce JNK or NFκB activation. Overexpression of Bcl10 has been shown to induce apoptosis in a manner dependent on CARD-mediated oligomerization. Bcl10 has also been shown to play a role in processing of caspase-9 to its active dimer. Other studies have shown that Bcl10 is not mutated in many human tumors and lymphomas.